Last reviewed · How we verify

B007 — Competitive Intelligence Brief

B007 (B007) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K inhibitor. Area: Oncology.

phase 2 PI3K inhibitor PI3K Oncology Small molecule Live · refreshed every 30 min

Target snapshot

B007 (B007) — Shanghai Jiaolian Drug Research and Development Co., Ltd. B007 is a small molecule that targets the PI3K/AKT signaling pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
B007 TARGET B007 Shanghai Jiaolian Drug Research and Development Co., Ltd phase 2 PI3K inhibitor PI3K
Itovebi inavolisib Pfizer marketed Kinase Inhibitor [EPC] phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA) 2024-01-01
Piqray alpelisib Novartis marketed PI3Kα 2019-01-01
Placebo followed by Fisetin Placebo followed by Fisetin Wake Forest University Health Sciences marketed Senolytic agent Multiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells
TGR-1202 TGR-1202 Vanderbilt-Ingram Cancer Center phase 3 PI3K delta inhibitor PI3K delta
GDC 695 GDC 695 Balmoral Medical company phase 3 PI3K delta inhibitor PI3K delta (p110δ)
Copanlisib (BAY 80-6946) Copanlisib (BAY 80-6946) Bayer phase 3 PI3K inhibitor PI3K (phosphatidylinositol 3-kinase), pan-class I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K inhibitor class)

  1. Addpharma Inc. · 4 drugs in this class
  2. AstraZeneca · 3 drugs in this class
  3. Bayer · 3 drugs in this class
  4. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 drugs in this class
  5. InventisBio Co., Ltd · 2 drugs in this class
  6. Orient Pharma Co., Ltd. · 2 drugs in this class
  7. Applied Biology, Inc. · 1 drug in this class
  8. Angitia Incorporated Limited · 1 drug in this class
  9. Aevi Genomic Medicine, LLC, a Cerecor company · 1 drug in this class
  10. BPGbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). B007 — Competitive Intelligence Brief. https://druglandscape.com/ci/b007. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: